Literature DB >> 11786964

Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells.

Akos Zsembery1, Wolfgang Jessner, Gerlinde Sitter, Carlo Spirlí, Mario Strazzabosco, Jürg Graf.   

Abstract

In view of the occurrence of hepatobiliary disorders in cystic fibrosis (CF) this study addresses the role of the cystic fibrosis transmembrane conductance regulator (CFTR) and of Ca(2+)-activated Cl(-) channels in promoting HCO3- secretion in bile ductular cells. Human cholangiocytes were isolated from control livers and from 1 patient with CF (DeltaF508/G542X mutations). Single channel and whole cell currents were analyzed by patch clamp techniques, and HCO3- secretion was determined by fluorometric analysis of the rate of recovery of intracellular pH following alkaline loading. In control cholangiocytes, both cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) catalytic subunit, activated CFTR Cl(-) channels that exhibited a nonrectifying conductance of 8 pS and appeared in clusters. Activation of Cl(-) current by cAMP was associated with an increase in the rate of HCO3- secretion. The basal rate of HCO3- secretion was lower in CF than in control cholangiocytes. In both control and CF cholangiocytes, raising intracellular Ca(2+) concentrations with ionomycin led to a parallel activation of Cl(-) current and HCO3- secretion. Consistent with reports that premature stop codon mutations (class I; e.g., G542X) can be read over by treatment with aminoglycoside antibiotics, exposure of CF cholangiocytes to gentamicin restored activation by cAMP of Cl(-) current and HCO3- secretion. The observation that activation of Ca(2+)-dependent Cl(-) channels can substitute for cystic fibrosis transmembrane conductance regulator (CFTR) in supporting HCO3- secretion and the efficacy of gentamicin in restoring CFTR function and HCO3- secretion in class I mutations are of potential clinical interest.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786964     DOI: 10.1053/jhep.2002.30423

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

1.  Editorial: cell biology of the hepatobiliary system.

Authors:  Renate Fuchs; Theresia Thalhammer
Journal:  Wien Med Wochenschr       Date:  2008

Review 2.  Functional anatomy of normal bile ducts.

Authors:  Mario Strazzabosco; Luca Fabris
Journal:  Anat Rec (Hoboken)       Date:  2008-06       Impact factor: 2.064

3.  Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies.

Authors:  Dominique Debray; Dominique Rainteau; Véronique Barbu; Myriam Rouahi; Haquima El Mourabit; Stéphanie Lerondel; Colette Rey; Lydie Humbert; Dominique Wendum; Charles-Henry Cottart; Paul Dawson; Nicolas Chignard; Chantal Housset
Journal:  Gastroenterology       Date:  2012-02-24       Impact factor: 22.682

Review 4.  Cholangiocyte anion exchange and biliary bicarbonate excretion.

Authors:  Jesús-M Banales; Jesus Prieto; Juan-F Medina
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

Review 5.  Purinergic regulation of duodenal surface pH and ATP concentration: implications for mucosal defence, lipid uptake and cystic fibrosis.

Authors:  J D Kaunitz; Y Akiba
Journal:  Acta Physiol (Oxf)       Date:  2011-01       Impact factor: 6.311

Review 6.  Nonsense-mediated decay in genetic disease: friend or foe?

Authors:  Jake N Miller; David A Pearce
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-28       Impact factor: 5.657

7.  Repression of CFTR activity in human MMNK-1 cholangiocytes induces sulfotransferase 1E1 expression in co-cultured HepG2 hepatocytes.

Authors:  Dongning He; Teresa W Wilborn; Josie L Falany; Li Li; Charles N Falany
Journal:  Biochim Biophys Acta       Date:  2008-09-11

8.  Role of Ca2+ -activated ion transport in the treatment of cystic fibrosis.

Authors:  Akos Zsembery; Dóra Hargitai
Journal:  Wien Med Wochenschr       Date:  2008

9.  PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.

Authors:  Ming Du; Xiaoli Liu; Ellen M Welch; Samit Hirawat; Stuart W Peltz; David M Bedwell
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

10.  Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.

Authors:  Ming Du; Kim M Keeling; Liming Fan; Xiaoli Liu; Timea Kovaçs; Eric Sorscher; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2006-03-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.